Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05355753 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
A Phase 1 study, sponsored by C4 Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT05355753 is a Phase 1 study that was terminated before completion, run by C4 Therapeutics. The registered enrollment target is 49 participants.
The verdict
NCT05355753, a Phase 1 study, was terminated before completion, sponsored by C4 Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
This is an open-label, non-randomized, first-in-human Phase 1/2 study designed to evaluate the safety and tolerability of CFT8634 in subjects with synovial sarcoma and SMARCB1-null tumors who: have received prior systemic therapy; have relapsed/refractory tumors; have unresectable or metastatic disease; and are not candidates for available therapies known to confer clinical benefit. The study will characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of CFT8634.
Interventions
- DRUG CFT8634
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2022-03-25 |
| Est. Completion | 2023-12-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05355753
The ClinicalTrials.gov registry entry for NCT05355753 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C4 Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CFT8634 is the first listed.
NCT05355753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05355753 about?
NCT05355753 is a clinical study titled "A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors". This is an open-label, non-randomized, first-in-human Phase 1/2 study designed to evaluate the safety and tolerability of CFT8634 in subjects with synovial sarcoma and SMARCB1-null tumors who: have received prior systemic therapy; have relapsed/refractory tumors; have unresectable or metastatic dise...
What is the current status of trial NCT05355753?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2022-03-25. Estimated completion is 2023-12-19.
What interventions are being tested in trial NCT05355753?
The interventions under investigation include: CFT8634 (DRUG).
Who is sponsoring clinical trial NCT05355753?
This trial is sponsored by C4 Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.